Arrowhead weekly recap: SHASTA-3/4 data and REDEMPLO plans

Recap cites Phase 3 SHASTA-3/4 results with ~80% triglyceride reduction and lower pancreatitis risk, plus plozasiran (REDEMPLO) launch/label expansion plans and $3—4B peak U.S. sales. Also notes readiness for ARO—MAPT tau data and pipeline broadening.